XMT-1522

N/A

Report date: 2024/02/05 13:57:16

Base Information

Drug NameXMT-1522
Drug Alias Nametrastuzumab-dolaflexinXMT-1522TAK-522
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > AF-HPA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics IncAdimab LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co LtdMersana Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A